Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed) | PA 19 034

FAQs: NIH SBIR/STTR Funding Opportunity PA-19-034 (IDG Understudied Proteins)

What is the main purpose of PA-19-034?

This NIH funding opportunity supports SBIR-style R43/R44 projects that turn "understudied" proteins from the Illuminating the Druggable Genome (IDG) initiative into commercially useful scientific products and, ultimately, starting points for drug discovery. The emphasis is on practical validation and productization so that IDG-generated knowledge and tools become adoptable by the broader biomedical and drug discovery communities.

What does "understudied proteins" mean in this context?

Within IDG, "understudied" refers to selected proteins in the druggable genome that are poorly characterized. IDG focuses on figuring out what these proteins do and how they might be targeted, with the goal of expanding the set of proteins that researchers can realistically pursue for biology and drug development.

What kinds of organizations are eligible to apply?

The eligible applicant pool is limited to small business concerns applying under the SBIR R43/R44 framework. The opportunity is not open to non-U.S. (foreign) institutions.

Are non-U.S. (foreign) institutions or non-domestic components eligible?

No. The announcement states it is not open to non-U.S. (foreign) institutions. In addition, non-domestic components of U.S. organizations are not eligible to apply. The description notes that foreign components may be permitted in limited cases consistent with NIH policy definitions and approvals.

What grant mechanisms does this opportunity use?

This is a discretionary NIH grant opportunity using the SBIR framework with R43/R44 mechanisms.

Are clinical trials allowed under this FOA?

No. The announcement explicitly states that clinical trials are not allowed.

How does this FOA connect to the Illuminating the Druggable Genome (IDG) initiative?

IDG is a Common Fund effort that generates and organizes resources to understand and target selected, poorly characterized proteins. This FOA is structured to bring small businesses into the IDG ecosystem so they can take IDG-generated knowledge, tools, and targets and push them toward real-world adoption, market readiness, and broader use in biomedical research and early drug discovery.

What is the role of small businesses in the IDG ecosystem under this opportunity?

The FOA assumes IDG has built a consortium that generates and organizes resources, while small companies are often better positioned to package those resources into scalable, validated offerings. Applicants are expected to complement the IDG centers by performing the validation, standardization, and productization work needed for commercialization.

Which IDG centers and efforts are mentioned, and what do they do?

The description references several IDG components: Data and Resource Generation Centers (DRGCs) that create datasets and reagents; a Knowledge Management Center (KMC) that organizes and integrates information; a Resource Dissemination and Outreach Center (RDOC) that helps get tools into users' hands; and Cutting Edge Informatics Tools (CEITs) efforts that develop advanced informatics capabilities.

Do applicants need to work directly with IDG centers?

The information provided does not state that direct collaboration is required. It does state that applicants are expected to complement these centers by taking IDG-related outputs (or approaches aligned with IDG priorities) and doing the practical work needed to move toward commercialization.

What types of projects are in scope?

Projects can span a range of early-stage translation activities, from proof-of-concept demonstrations to more development-oriented assay development and validation, and even initiating preclinical drug discovery efforts, as long as the work stays within the intended scope for early research and commercialization planning. The unifying theme is reducing practical barriers that keep understudied proteins out of mainstream research and drug development pipelines.

What is an example of a proof-of-concept project under this FOA?

An application could focus on demonstrating that a particular understudied protein can be interrogated reliably, or that a new tool meaningfully improves the ability to study that protein. The key is showing practical feasibility in a way that supports later adoption and product development.

What is an example of a more development-oriented project under this FOA?

The FOA allows assay development and assay validation work that makes a target more tractable for screening and lead discovery. This can include building standardized assays and generating reproducibility data that make the target usable in real-world discovery workflows.

Can projects include preclinical drug discovery activities?

Yes, the FOA allows projects that begin to initiate preclinical drug discovery efforts, provided they remain within the intended scope for early research and commercialization planning. Clinical trials are not allowed.

What is the common thread across all acceptable project types?

All projects should reduce practical barriers that prevent understudied proteins from being used broadly in biology and drug development, and should do so in a way that results in a product, service, or platform that a small business can realistically bring to market.

What kinds of deliverables or outputs does NIH appear to be looking for?

Examples of adoptable outputs include high-quality reagents with demonstrated performance, standardized assays with reproducibility data, datasets packaged for broad use, or informatics tools that make IDG knowledge easier to apply in real workflows. The focus is on validated, usable offerings rather than academic prototypes.

What does "productization" mean here?

In this FOA, productization refers to the practical steps needed to turn IDG-linked knowledge, tools, or targets into something market-ready. That includes validation, standardization, packaging, and demonstrating that the output can be manufactured, supported, distributed, and reliably used by customers.

How important is commercialization in the application?

Commercialization is a core expectation. The description indicates that proposals should connect the technical plan to a credible commercialization path, showing the end result is something that can be brought to market and adopted by biomedical research or early drug discovery customers.

What should a strong application clearly explain?

A strong application would typically explain (1) why a specific understudied protein or class of proteins matters, (2) what IDG-linked gap is being addressed, (3) how the proposed work will produce a validated and adoptable output, and (4) how that output will realistically be commercialized and supported.

Does the opportunity focus on certain scientific areas within NIH?

The opportunity sits within NIH health-related program areas and is tied to multiple CFDA listings, reflecting cross-cutting relevance to multiple NIH institutes and centers interested in improving druggability and functional understanding of neglected protein targets.

Is the goal to create academic research outputs or market-ready tools?

The FOA emphasizes moving beyond academic prototypes. The expected trajectory is toward validated, scalable outputs that can be adopted in real workflows and supported as commercial products, services, or platforms.